1.Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration.
Yuan-Yi MIAO ; Cong-Min XU ; Min XIA ; Huai-Qiu ZHU ; Yu-Qing CHEN
Chinese Medical Journal 2018;131(23):2792-2799
Background:
Hyperphosphatemia is a risk factor associated with mortality in patients on maintenance hemodialysis. Gut absorption of phosphate is the major source. Recent studies indicated that the intestinal flora of uremic patients changed a lot compared with the healthy population, and phosphorus is an essential element of bacterial survival and reproduction. The purpose of this study was to explore the role of intestinal microbiota in phosphorus metabolism.
Methods:
A prospective self-control study was performed from October 2015 to January 2016. Microbial DNA was isolated from the stools of 20 healthy controls and 21 maintenance hemodialysis patients. Fourteen out of the 21 patients were treated with lanthanum carbonate for 12 weeks. Thus, stools were also collected before and after the treatment. The bacterial composition was analyzed based on 16S ribosomal RNA pyrosequencing. Bioinformatics tools, including sequence alignment, abundance profiling, and taxonomic diversity, were used in microbiome data analyses. Correlations between genera and the serum phosphorus were detected with Pearson's correlation. For visualization of the internal interactions and further measurement of the microbial community, SparCC was used to calculate the Spearman correlation coefficient with the corresponding P value between each two genera.
Results:
Thirteen genera closely correlated with serum phosphorus and the correlation coefficient was above 0.4 (P < 0.05). We also found that 58 bacterial operational taxonomic units (OTUs) were significantly different and more decreased OTUs were identified and seven genera (P < 0.05) were obviously reduced after using the phosphate binder. Meanwhile, the microbial richness and diversity presented downward trend in hemodialysis patients compared with healthy controls and more downward trend after phosphorus reduction. The co-occurrence network of genera revealed that the network complexity of hemodialysis patients was significantly higher than that of controls, whereas treatment with lanthanum carbonate reduced the network complexity.
Conclusions
Gut flora related to phosphorus metabolism in hemodialysis patients, and improving intestinal microbiota may regulate the absorption of phosphate in the intestine. The use of phosphate binder lanthanum carbonate leads to a tendency of decreasing microbial diversity and lower network complexity.
Child
;
Female
;
Gastrointestinal Microbiome
;
drug effects
;
physiology
;
Humans
;
Lanthanum
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphorus
;
metabolism
;
Prospective Studies
;
Renal Dialysis
;
Risk Factors
;
Uremia
;
drug therapy
;
metabolism
;
microbiology
2.Early diagnosis, prevention and treatment for calcific uremic arteriolopathy.
Yueyi ZHOU ; Hao ZHANG ; Jian SUN ; Ying JI ; Jishi LIU
Journal of Central South University(Medical Sciences) 2018;43(11):1251-1256
Calcific uremic arteriopathy (CUA), termed calciphylaxis, is a rare but highly fatal clinical syndrome. There is no clearly laboratory diagnostic criteria for CUA. The medium and small arterial calcification and microthrombosis discovered by skin biopsy, radiologic imaging,bone scan and the evidence of activation of the bone morphogenetic protein signal (BMPs) transduction pathway are useful for early diagnosis of this disease. The common therapies (including intravenous sodium thiosulfate (STS) and bisphosphonates, hyperbaric oxygen therapy and other symptomatic supports) are used for the management of wounds, pain, nutrition, dialysis and so on. Controlling the chronic kidney disease-mineral and bone disorder (CKD-MBD) and some complications of dialysis and drugs (such as warfarin, active vitamin D) can prevent CUA. However, CUA patients still have poor prognosis and high mortality. Since some patients progress rapidly, it is of great importance to make early diagnosis and provide effective treatments with multidisciplinary management.
Calciphylaxis
;
diagnosis
;
prevention & control
;
therapy
;
Early Diagnosis
;
Humans
;
Renal Dialysis
;
Uremia
;
Warfarin
3.Understanding and Therapeutic Strategies of Chinese Medicine on Gut-Derived Uremic Toxins in Chronic Kidney Disease.
Chinese journal of integrative medicine 2018;24(6):403-405
Chronic kidney disease (CKD) is a major disease that threatens human health. With the progression of CKD, the risk of cardiovascular death increases, which is associated with the elevated levels of uremic toxins (UTs). Representative toxins such as indoxyl sulfate and p-cresyl sulfate are involed in CKD progression and cardiovascular events inseparable from the key role of endothelial dysfunction. The therapeutic strategies of UTs are aimed at signaling pathways that target the levels and damage of toxins in modern medicine. There is a certain relevance between toxins and "turbid toxin" in the theory of Chinese medicine (CM). CM treatments have been demonstrated to reduce the damage of gut-derived toxins to the heart, kidney and blood vessels. Modern medicine still lacks evidence-based therapies, so it is necessary to explore the treatments of CM.
Humans
;
Intestinal Mucosa
;
metabolism
;
Medicine, Chinese Traditional
;
Renal Insufficiency, Chronic
;
drug therapy
;
Signal Transduction
;
drug effects
;
Toxins, Biological
;
analysis
;
metabolism
;
Uremia
;
metabolism
4.Operation of huge pseudoaneurysm with low- dose coagulant factor 8 replacement therapy on a severe hemophilia A patient with uremia:a case report.
Chinese Journal of Hematology 2015;36(9):764-764
Aneurysm, False
;
surgery
;
Factor VIII
;
therapeutic use
;
Hemophilia A
;
drug therapy
;
Humans
;
Uremia
5.Effect of alprostadil on serum level of miRNA-155 in uremic patients.
Wei ZHANG ; Linjing SHI ; Hao ZHANG ; Chen WANG ; Shan GAO ; Yarong MA ; Wei LI ; Jian LIU ; Jinwei WANG ; Jishi LIU
Journal of Central South University(Medical Sciences) 2015;40(7):735-741
OBJECTIVE:
To investigate the serum levels of microRNA-155 (miR-155) and interleukin-6 (IL-6) in uremic dialysis patients and to evaluate the effect of alprostadil (A) on them.
METHODS:
A total of 81 chronic kidney disease (CKD) uremic patients were divided into 4 groups: the peritoneal dialysis group (PD group, n=20), the peritoneal dialysis plus alprostadil group (PD+A group, n=20), the hemodialysis group (HD group, n=21), the hemodialysis plus alprostadil group (HD+A group, n=20). Sixteen healthy people were taken as the normal control (NC) group. The peripheral blood of all objects were collected for serum preparation. The expression of miRNA-155 was determined by real-time qPCR and the serum level of IL-6 was measured by ELISA. Experimental and clinical data of all the objects were collected.
RESULTS:
Serum levels of miRNA-155 and IL-6 were increased in all dialysis patients groups compared with NC group (P<0.05); miRNA-155 expression in PD+A group was down-regulated compared with PD group or HD group (P<0.05); the levels of IL-6 in PD+A and HD+A group were significantly decreased compared with PD group or HD group (P<0.05). Correlation analysis showed that serum level of miR-155 was positively correlated with the level of IL-6 as well as high-sensitivity C-reactive protein (hs-CRP), while miR-155 was negatively correlated with HDL and albumin (P<0.01). Linear stepwise regression analysis indicated that serum miR-155 was independently associated with albumin and hs-CRP.
CONCLUSION
Serum miRNA-155 and IL-6 in uremic dialysis patients were remarkably increased compared to healthy objects. Serum miRNA-155 was positively correlated with the level of IL-6 as well as hs-CRP, while miR-155 was negatively correlated with HDL and albumin. Alprostadil could ameliorate the inflammatory conditions of uremic dialysis patients by inhibition of the IL-6 expression. Serum miRNA-155 may be a novel target for the treatment of uremic dialysis patients.
Alprostadil
;
therapeutic use
;
C-Reactive Protein
;
metabolism
;
Case-Control Studies
;
Humans
;
Interleukin-6
;
blood
;
MicroRNAs
;
blood
;
Peritoneal Dialysis
;
Regression Analysis
;
Renal Dialysis
;
Renal Insufficiency, Chronic
;
therapy
;
Uremia
;
blood
;
drug therapy
6.An Overlooked Cause of Impaired Consciousness in a Hemodialysis Patient.
Jun Young LEE ; Kyung Pyo KANG ; Won KIM ; Sung Kwang PARK ; Sik LEE
The Korean Journal of Internal Medicine 2012;27(3):367-367
No abstract available.
Aged
;
Anti-Bacterial Agents/*adverse effects
;
Anticonvulsants/therapeutic use
;
Cephalosporins/*adverse effects
;
Consciousness Disorders/diagnosis/drug therapy/*etiology
;
Diabetic Nephropathies/complications/*therapy
;
Electroencephalography
;
Female
;
Humans
;
Pneumonia, Bacterial/complications/*drug therapy
;
*Renal Dialysis
;
Status Epilepticus/diagnosis/drug therapy/*etiology
;
Treatment Outcome
;
Uremia/therapy
7.Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.
Jifeng SUN ; Yarong WANG ; Jie YANG ; Dewei DU ; Zhanting LI ; Junxia WEI ; Angang YANG
Experimental & Molecular Medicine 2012;44(11):674-683
Relative deficiency in production of glycoprotein hormone erythropoietin (Epo) is a major cause of renal anemia. This study planned to investigate whether the hypoxia-regulated system of Epo expression, constructed by fusing Epo gene to the chimeric phosphoglycerate kinase (PGK) hypoxia response elements (HRE) in combination with cytomegalovirus immediate-early (CMV IE) basal gene promoter and delivered by plasmid intramuscular injection, might provide a long-term physiologically regulated Epo secretion expression to correct the anemia in adenine-induced uremic rats. Plasmid vectors (pHRE-Epo) were synthesized by fusing human Epo cDNA to the HRE/CMV promoter. Hypoxia-inducible activity of this promoter was evaluated first in vitro and then in vivo in healthy and uremic rats (n = 30 per group). The vectors (pCMV-Epo) in which Epo expression was directed by a constitutive CMV gene promoter served as control. ANOVA and Student's t-test were used to analyze between-group differences. A high-level expression of Epo was induced by hypoxia in vitro and in vivo. Though both pHRE-Epo and pCMV-Epo corrected anemia, the hematocrit of the pCMV-Epo-treated rats exceeded the normal (P < 0.05), but that of the pHRE-Epo-treated rats didn't. Hypoxia-regulated system of Epo gene expression constructed by fusing Epo to the HRE/CMV promoter and delivered by plasmid intramuscular injection may provide a long-term and stable Epo expression and secretion in vivo to correct the anemia in adenine-induced uremic rats.
Anemia/blood/*therapy
;
Animals
;
Base Sequence
;
Blood Urea Nitrogen
;
Cell Hypoxia
;
Creatinine/blood
;
Erythropoietin/biosynthesis/*genetics/secretion
;
Gene Expression Regulation
;
Genes, Reporter
;
Genetic Therapy
;
HeLa Cells
;
Humans
;
Injections, Intramuscular
;
Kidney/pathology
;
Luciferases, Firefly/biosynthesis/genetics
;
Molecular Sequence Data
;
Plasmids/*genetics
;
Promoter Regions, Genetic
;
Rats
;
Rats, Sprague-Dawley
;
Recombinant Proteins/biosynthesis/genetics/secretion
;
Response Elements
;
Transcriptional Activation
;
Uremia/blood/*therapy
9.Application of Cystatin C Reduction Ratio to High-Flux Hemodialysis as an Alternative Indicator of the Clearance of Middle Molecules.
Joon Sung PARK ; Gheun Ho KIM ; Chong Myung KANG ; Chang Hwa LEE
The Korean Journal of Internal Medicine 2010;25(1):77-81
BACKGROUND/AIMS: Although high-flux (HF) dialyzers with enhanced membrane permeability are widely used in current hemodialysis (HD) practice, urea kinetic modeling is still being applied to indicate the adequacy of both low-flux (LF) and HF HD. In comparison with urea (molecular weight, 60 Da) and beta2-microglobulin (beta2MG, 12 kDa), cystatin C (CyC, 13 kDa) is a larger molecule that has attractive features as a marker for assessing solute clearance. We postulated that CyC might be an alternative for indicating the clearance of middle molecules (MMs), especially with HF HD. METHODS: Eighty-nine patients were divided into LF and HF groups. Using single pool urea kinetic modeling, the urea reduction ratio (URR) and equilibrated Kt/Vurea (eKt/Vurea) were calculated. The serum CyC concentrations were measured using particle-enhanced immunonephelometry. As indices of the middle molecular clearance, the reduction ratios of beta2MG and CyC were calculated. RESULTS: The beta2MG reduction ratio (beta2MGRR) and CyC reduction ratio (CyCRR) were higher in the HF group compared to the LF group. However, the URR and eKt/Vurea did not differ between the two groups. The CyCRR was significantly correlated with the eKt/Vurea and beta2MGRR (r = 0.47 and 0.69, respectively, both p < 0.0001). CONCLUSIONS: Compared to the LF dialyzer, the HF dialyzer removed CyC and beta2MG more efficiently. Unlike the beta2MGRR, the CyCRR was correlated with the eKt/Vurea and beta2MGRR. This study suggests a role for the CyCRR as an alternative indicator of the removal of MMs.
Adult
;
Aged
;
Biological Markers/blood
;
Case-Control Studies
;
Cystatin C/*blood
;
Female
;
Hemodialysis Solutions
;
Humans
;
Kidney Failure, Chronic/*blood/*therapy
;
Male
;
Middle Aged
;
Models, Biological
;
Nephelometry and Turbidimetry/*methods
;
Renal Dialysis/*methods
;
Urea/blood
;
Uremia/blood/therapy
;
beta 2-Microglobulin/blood
10.Levels of main platelet thrombin receptors in older chronic haemodialysis patients.
Yan LI ; Lin SHEN ; Rui CHEN ; Fu-rong LU ; Jing LI ; Jian-guo LIU
Chinese Medical Journal 2010;123(17):2495-2496
Aged
;
Aged, 80 and over
;
Blood Platelets
;
chemistry
;
Humans
;
Receptor, PAR-1
;
blood
;
Receptors, Thrombin
;
blood
;
Renal Dialysis
;
Uremia
;
blood
;
therapy

Result Analysis
Print
Save
E-mail